|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2600121907 |
|
最近更新日期: Date of Last Refreshed on: |
2026-04-07 10:46:11 |
|
注册时间: Date of Registration: |
2026-04-07 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
母乳源免疫调节因子调控婴儿免疫发育的机制研究 |
|
Public title: |
Research on the Mechanism of Immunomodulatory Factors Derived from Breast Milk Regulating Immune Development in Infants |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
母乳源免疫调节因子调控婴儿免疫发育的机制研究 |
|
Scientific title: |
Research on the Mechanism of Immunomodulatory Factors Derived from Breast Milk Regulating Immune Development in Infants |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
余仁强 |
研究负责人: |
余仁强 |
|
Applicant: |
Renqiang Yu |
Study leader: |
Renqiang Yu |
|
申请注册联系人电话: Applicant telephone: |
+86 150 5067 6990 |
研究负责人电话: Study leader's telephone: |
+86 150 5067 6990 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
yurenqiang553@163.com |
研究负责人电子邮件: Study leader's E-mail: |
yurenqiang553@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
江苏省无锡市梁溪区槐树巷48号 |
研究负责人通讯地址: |
江苏省无锡市梁溪区槐树巷48号 |
|
Applicant address: |
No. 48, Huaishu Lane, Liangxi District, Wuxi City, Jiangsu Province |
Study leader's address: |
No. 48, Huaishu Lane, Liangxi District, Wuxi City, Jiangsu Province |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
无锡市妇幼保健院 |
||
|
Applicant's institution: |
Wuxi Maternal and Child Health Hospital |
||
|
研究负责人所在单位: |
无锡市妇幼保健院 |
||
|
Affiliation of the Leader: |
Wuxi Maternal and Child Health Hospital |
||
|
是否获伦理委员会批准: |
是/Yes |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
YLSL2025-103-01 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
无锡市妇幼保健院医学伦理审查委员会 |
||
|
Name of the ethic committee: |
Medical Ethics Review Committee of Wuxi Maternal and Child Health Hospital |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2026-01-27 00:00:00 |
||
|
伦理委员会联系人: |
孙琰 |
||
|
Contact Name of the ethic committee: |
Yan Sun |
||
|
伦理委员会联系地址: |
江苏省无锡市梁溪区槐树巷48号 |
||
|
Contact Address of the ethic committee: |
No. 48, Huaishu Lane, Liangxi District, Wuxi City, Jiangsu Province |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 510 8191 0353 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
江苏省无锡市妇幼保健院 |
||||||||||||||||||||||
|
Primary sponsor: |
Wuxi Maternal and Child Health Hospital, Jiangsu Province |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
江苏省无锡市梁溪区槐树巷48号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No. 48, Huaishu Lane, Liangxi District, Wuxi City, Jiangsu Province |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
自选课题(自筹) |
||||||||||||||||||||||
|
Source(s) of funding: |
Self-selected topic (self-funded) |
||||||||||||||||||||||
|
Target disease: |
Immune imbalance in infants and young children |
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
横断面 |
||||||||||||||||||||||
|
Study design: |
Cross-sectional |
||||||||||||||||||||||
|
研究目的: |
主要研究目的:针对本项目的样本分析研究,主要目的是:通过体外功能实验明确母乳源肽和益生菌作用机制。利用新生儿脐带血来源的免疫细胞建立体外模型,直接验证上述关键母乳肽以及特定母乳源益生菌对免疫细胞(如巨噬细胞、T细胞)分化和功能的调节作用,从而将母乳成分的发现与具体的生物学功能联系起来。 次要研究目的:针对本项目的样本分析研究,次要目的:探究上述母乳肽及益生菌所诱导的免疫细胞(如巨噬细胞极化、T细胞亚群分化)变化谱式,明确新生儿期特有的免疫应答模式,并与已知的成人免疫应答进行初步比较。 |
||||||||||||||||||||||
|
Objectives of Study: |
Main research objective: For the sample analysis study of this project, the main objective is: Through in vitro functional experiments, to clarify the mechanism of action of breast milk peptides and probiotics. Using immune cells derived from neonatal umbilical cord blood to establish an in vitro model, directly verify the regulatory effects of the aforementioned key breast milk peptides and specific breast milk-derived probiotics on the differentiation and function of immune cells (such as macrophages, T cells), thereby linking the discovery of breast milk components with specific biological functions. Secondary research objective: For the sample analysis study of this project, the secondary objective is: To explore the patterns of changes in immune cells (such as macrophage polarization, T cell subpopulation differentiation) induced by these breast milk peptides and probiotics, clarify the unique immune response patterns during the neonatal period, and conduct a preliminary comparison with the known adult immune responses. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1:新生儿状况:单胎、足月(孕37-42周)出生,Apgar评分>7分,无重大先天性疾病、遗传代谢病或出生窒息等需重症监护的情况。 2:母亲健康状况:无重大慢性疾病、活动性传染病或自身免疫性疾病。 3:知情同意:产妇本人充分了解脐带血采集仅用于本研究,并自愿签署单独的书面知情同意书。 |
||||||||||||||||||||||
|
Inclusion criteria |
1: Neonatal condition: Single birth, full-term (gestational age 37-42 weeks), with Apgar score > 7, and no major congenital diseases, genetic metabolic disorders, or birth asphyxia requiring intensive care; 2: Mother's health condition: No major chronic diseases, active infectious diseases, or autoimmune diseases; 3: Informed consent: The mother fully understood that the collection of umbilical cord blood was only for this study and voluntarily signed a separate written informed consent form. |
||||||||||||||||||||||
|
排除标准: |
1:母亲疾病/用药:近期(如产前/产后一周内)使用可能影响免疫系统的药物(如大剂量激素、免疫抑制剂等)。 2:婴儿状况:婴儿被诊断为重大先天性疾病、遗传代谢病或需在新生儿重症监护室长期治疗。 3:其他因素:研究者判断存在任何可能影响样本代表性或增加研究风险的其他情况。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1: Mother's illness/medication: Recently (within one week before or after delivery), the mother has used drugs that may affect the immune system (such as high-dose hormones, immunosuppressants, etc.); 2: Infant condition: The infant has been diagnosed with a major congenital disease, genetic metabolic disorder, or requires long-term treatment in the neonatal intensive care unit; 3: Other factors: The researcher determines that there are any other circumstances that may affect the representativeness of the sample or increase the risk of the study. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2026-01-01 00:00:00至 To 2027-12-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从From 2026-04-10 00:00:00 至 To 2027-12-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
女性 |
Gender: |
Female |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
None |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
|
|
Blinding: |
|
是否共享原始数据: IPD sharing |
No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
无 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
None |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
所有纸质版《脐带血捐赠者信息登记表》内容,将由两名独立的数据录入员使用加密的电子数据库(如RedCap或专用Excel模板)进行双份录入。 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
All the contents of the paper version of the umbilical cord blood donor information registration form will be entered in duplicate by two independent data entry personnel using an encrypted electronic database (such as redcap or a special excel template). |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |